PROGRAF-XL tacrolimus 5 mg prolonged-release capsule blister pack Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

prograf-xl tacrolimus 5 mg prolonged-release capsule blister pack

astellas pharma australia pty ltd - tacrolimus, quantity: 5 mg - capsule, modified release - excipient ingredients: lactose monohydrate; titanium dioxide; hypromellose; sodium lauryl sulfate; iron oxide red; magnesium stearate; iron oxide yellow; ethylcellulose; gelatin; butan-1-ol; hyprolose; purified water; industrial methylated spirit; simethicone; lecithin; ethanol; shellac; strong ammonia solution; sulfuric acid - prograf-xl is indicated for use as an adjunct to liver, kidney, lung or heart allograft transplantation in adults and children.

PROGRAF-XL tacrolimus 1 mg prolonged-release capsule blister pack Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

prograf-xl tacrolimus 1 mg prolonged-release capsule blister pack

astellas pharma australia pty ltd - tacrolimus, quantity: 1 mg - capsule, modified release - excipient ingredients: hypromellose; iron oxide yellow; gelatin; sodium lauryl sulfate; titanium dioxide; ethylcellulose; iron oxide red; magnesium stearate; lactose monohydrate; butan-1-ol; hyprolose; purified water; industrial methylated spirit; simethicone; lecithin; ethanol; shellac; strong ammonia solution; sulfuric acid - prograf-xl is indicated for use as an adjunct to liver, kidney, lung or heart allograft transplantation in adults and children.

PROGRAF-XL tacrolimus 0.5 mg prolonged-release capsule blister pack Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

prograf-xl tacrolimus 0.5 mg prolonged-release capsule blister pack

astellas pharma australia pty ltd - tacrolimus, quantity: 0.5 mg - capsule, modified release - excipient ingredients: iron oxide yellow; hypromellose; iron oxide red; titanium dioxide; lactose monohydrate; ethylcellulose; magnesium stearate; sodium lauryl sulfate; gelatin; butan-1-ol; hyprolose; purified water; industrial methylated spirit; simethicone; lecithin; ethanol; shellac; strong ammonia solution; sulfuric acid - prograf-xl is indicated for use as an adjunct to liver, kidney, lung or heart allograft transplantation in adults and children.

BETMIGA mirabegron 50 mg film-coated prolonged-release tablet blister pack Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

betmiga mirabegron 50 mg film-coated prolonged-release tablet blister pack

astellas pharma australia pty ltd - mirabegron, quantity: 50 mg - tablet, modified release - excipient ingredients: macrogol 2000000; macrogol 8000; purified water; butylated hydroxytoluene; hyprolose; magnesium stearate; hypromellose; iron oxide yellow - symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence in patients with overactive bladder (oab) syndrome.

BETMIGA mirabegron 25 mg film-coated prolonged-release tablet blister pack Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

betmiga mirabegron 25 mg film-coated prolonged-release tablet blister pack

astellas pharma australia pty ltd - mirabegron, quantity: 25 mg - tablet, modified release - excipient ingredients: butylated hydroxytoluene; magnesium stearate; hyprolose; purified water; macrogol 2000000; macrogol 8000; hypromellose; iron oxide yellow; iron oxide red - symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence in patients with overactive bladder (oab) syndrome.

VESICARE solifenacin succinate 10mg tablet blister pack Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

vesicare solifenacin succinate 10mg tablet blister pack

astellas pharma australia pty ltd - solifenacin succinate, quantity: 10 mg - tablet, film coated - excipient ingredients: hypromellose; lactose monohydrate; maize starch; magnesium stearate; titanium dioxide; macrogol 8000; purified talc; iron oxide red - vesicare is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency or increased urinary frequency.

VESICARE solifenacin succinate 5mg tablet blister pack Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

vesicare solifenacin succinate 5mg tablet blister pack

astellas pharma australia pty ltd - solifenacin succinate, quantity: 5 mg - tablet, film coated - excipient ingredients: magnesium stearate; hypromellose; lactose monohydrate; maize starch; titanium dioxide; iron oxide yellow; purified talc; macrogol 400 - vesicare is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency or increased urinary frequency.

FLOMAXTRA tamsulosin hydrochloride 400 microgram prolonged release tablet blister pack Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

flomaxtra tamsulosin hydrochloride 400 microgram prolonged release tablet blister pack

astellas pharma australia pty ltd - tamsulosin hydrochloride, quantity: 400 microgram - tablet, modified release - excipient ingredients: colloidal anhydrous silica; macrogol 8000; macrogol 7000000; hypromellose; butylated hydroxytoluene; iron oxide yellow; magnesium stearate - for the relief of lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph).

XOSPATA gilteritinib (as fumarate) 40 mg film-coated tablet blister pack Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

xospata gilteritinib (as fumarate) 40 mg film-coated tablet blister pack

astellas pharma australia pty ltd - gilteritinib fumarate, quantity: 44.2 mg - tablet, film coated - excipient ingredients: hyprolose; magnesium stearate; mannitol; titanium dioxide; macrogol 8000; hypromellose; purified talc; iron oxide yellow - xospata is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukaemia (aml) with a flt3 mutation.

MYCAMINE micafungin (as sodium) 100 mg powder for injection vial Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

mycamine micafungin (as sodium) 100 mg powder for injection vial

astellas pharma australia pty ltd - micafungin sodium, quantity: 101.73 mg (equivalent: micafungin, qty 100 mg) - injection, powder for - excipient ingredients: citric acid; sodium hydroxide; lactose monohydrate - mycamine is indicated for: ? treatment of invasive candidiasis in children and adults ? treatment of oesophageal candidiasis in adults, adolescents greater than or equal to 16 years of age and the elderly patients for whom intravenous therapy is appropriate ? prophylaxis of candida infection in children and adult patients undergoing allogeneic haematopoietic stem cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count < 500 cells/?l) for 10 or more days.